Moderna
About
Moderna Inc. (NASDAQ: MRNA) is a biotechnology company pioneering messenger RNA therapeutics and vaccines, having risen to global prominence through the development of one of the first authorized COVID-19 vaccines, Spikevax, which generated tens of billions in revenue and validated the mRNA platform. Beyond COVID-19, the company is advancing a broad pipeline of mRNA-based candidates targeting respiratory syncytial virus, influenza, cancer, rare diseases, and autoimmune conditions, leveraging its proprietary lipid nanoparticle delivery technology. As an investment, Moderna represents a high-conviction bet on the transformative potential of mRNA technology across multiple disease areas, though investors must weigh declining COVID vaccine revenues against the promise of its expanding pipeline.
Biotech Stocks
Moderna exemplifies the innovative potential of biotech investing, having built an entire therapeutic platform around mRNA technology that extends far beyond its landmark COVID-19 vaccine into oncology, rare diseases, and personalized medicine, offering investors exposure to what could become a foundational technology in modern medicine.
Key Financials MRNA
Price
$42.23
Change (1D)
+5.29%
Change (30D)
+43.20%
Change (60D)
+70.56%
Change (90D)
+53.34%
Change (180D)
+62.11%
Change (1Y)
+38.30%
Change (5Y)
-76.48%
P/E Ratio
-20.21
EPS (TTM)
$-2.09
52-Week Range
$22.28 — $55.20
50-Day MA
$36.74
Volume
16.33M
Data updated Feb 15 · Source: Twelve Data
